Thus, decreased CD19 and CD22 surface expression due to low IKAROS levels reduces the efficacy of CD19- and CD22-targeted therapies and B-ALL cell killing, demonstrating that IKAROSlow cells have a survival advantage in the face of these therapies (Fig. 5). The gene discussed is CD22; the disease is precursor B-cell acute lymphoblastic leukemia.